Drug Profile
Research programme: Eg5 kinesin inhibitors - SuperGen
Alternative Names: Eg5 kinesin inhibitor - SuperGenLatest Information Update: 20 Apr 2011
Price :
$50
*
At a glance
- Originator SuperGen
- Class
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Leukaemia; Solid tumours
Most Recent Events
- 20 Apr 2011 No development reported for Leukaemia in USA (unspecified route)
- 20 Apr 2011 No development reported for Solid tumours in USA (unspecified route)